{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"the-disc-stack","urls":{"read":"https://miscsubjects.com/api/articles/the-disc-stack/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/the-disc-stack/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/the-disc-stack/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/the-disc-stack/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/the-disc-stack/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/the-disc-stack/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/the-disc-stack/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"the-disc-stack","title":"The Disc Recovery Stack","register":"essay","tags":["stack","disc","herniated-disc","degenerative-disc-disease","peptides"],"updated_at":"2026-08-04T20:35:13.192Z","body_excerpt":"A disc stack is two or more compounds taken at the same time for a worn or bulging spinal disc — most often BPC-157 with TB-500, sometimes with ARA-290 added for the leg pain, sometimes alongside a weight-loss drug. Each compound is aimed at a different step in how a disc fails.\n\nUnderneath all of it is one arithmetic. A disc is being broken down at some speed and built back at some other speed, and how your back feels in six months is decided by which of the two is faster. Every single thing on the list below — walking, smoking, a needle, a tablet, a vial — moves one of those two speeds by some amount. What decides your outcome is not any one of those amounts. It is the sum.\n\nThat sum is what almost nothing has been measured on. Nobody with a bad disc runs one variable. They are walking or not walking, sleeping six hours or eight, carrying an extra thirty pounds or not, taking ibuprofen daily or not, and injecting one compound or three — all in the same week. The individual numbers below are real and mostly good. The combined numbers, with three exceptions, do not exist, and where they do exist one of them came back negative.\n\n## A worn disc is two speeds, and the slow one is the blood supply\n\nThe disc is the largest structure in the body with almost no blood supply of its own. Small vessels reach the outermost fibres of the tough outer ring and stop there; the soft centre is fed by fluid seeping through the bone above and below it. Every repair process in the body runs on blood delivery, so the disc rebuilds more slowly than any other load-bearing tissue you own.\n\n[[embed:source:s1]]\n\nThat does not mean the rebuild side loses. Pooled across eleven cohort studies of people managed without surgery, 66.66% of herniated discs shrank on their own (95% CI 51% to 69%). In the United Kingdom subset the figure was 82.94%; in the Japanese subset, 62.58%.\n\n[[embed:source:s2]]\n\nThe shrinking is done by immune cells that treat the displaced fragment as foreign material, digest it, and bring new blood vessels in behind them to carry the debris away.\n\n[[embed:source:s3]]\n\nTwo things follow from that pair of facts, and they set up everything else. First, the rebuild side already wins about two times in three with nobody doing anything. Second, the mechanism it wins by is inflammation plus new blood vessel growth — which is precisely the mechanism a daily anti-inflammatory tablet is designed to shut down.\n\n[[embed:degenerative-disc-disease]]\n\n## Genetics puts a number on each thing that wears a disc down\n\nObservational studies of back pain are badly confounded: people who smoke also move less, weigh more and sleep worse, so an association tells you almost nothing about direction. Mendelian randomisation gets around that by using inherited gene variants as the exposure — you are assigned your variants at conception, before any lifestyle exists, so the arrow can only point one way.\n\nA 2026 synthesis pooled twenty such studies in people against disc degeneration and put an odds ratio on each factor. An odds ratio of 1.26 means roughly a 26% higher chance of the outcome per unit of the exposure.\n\n| What moves the breakdown speed | Odds of disc degeneration | How to move it |\n|---|---|---|\n| Time spent sitting watching television | 1.78 (1.52–2.08) | Stand up and walk; this is the largest lifestyle number in the set |\n| Body mass index | 1.26 (1.14–1.38) | Weight loss by any route |\n| Waist circumference | 1.26 (1.04–1.53) | Same lever, measured at the belly |\n| Smoking, ever having started | 1.22 (1.12–1.33) | Stopping — with a caveat below |\n| Triglycerides in the blood | 1.08 (1.03–1.13) | Diet, weight loss, movement |\n| Type 2 diabetes | 1.05 (1.03–1.07) | Glucose control |\n| Higher bone density | 1.20 (1.15–1.25) | Not a lever — you would not lower it on purpose |\n\n[[embed:source:s8]]\n\nThe body-mass row has a second, condition-specific measurement behind it. A meta-analysis of observational studies in people found overweight raised the odds ","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c2","text":"The body already removes most herniations: ~67% resorb spontaneously via a macrophage- and blood-vessel-driven process, so recovery means supporting an existing mechanism, not forcing a new one.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s2","s3"],"why_material":"The stack works with the body's own regenerative process.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Body weight is a modifiable driver: overweight and obesity raise the odds of sciatica and disc herniation, making load reduction the one lever a person directly controls.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s4"],"why_material":"Justifies the unload-the-spine arm.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c5","text":"A human meta-analysis found stem-cell injection may reduce discogenic pain and disability, the first real human signal that the disc is a regeneration target - though still small and early.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s6"],"why_material":"Anchors the regenerative premise in real, if limited, human data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c1","text":"The disc is the body's largest avascular structure and repairs poorly on its own, which is the central obstacle any disc-recovery strategy must overcome.","tier":"mechanistic","interaction_risk":false,"status":"active","source_ids":["s1"],"why_material":"The bottleneck every arm of the stack is trying to address.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c4","text":"TNF-alpha and IL-1beta drive both disc degeneration and the inflammatory nerve pain of a herniation, making the inflammatory signal a shared target.","tier":"mechanistic","interaction_risk":false,"status":"active","source_ids":["s5"],"why_material":"Justifies calming the nerve/inflammation rather than only masking pain.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9820240/","title":"Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration","quote":"The IVD is one of the avascular tissues which only received small arteries supplying the outermost peripheral fibers of the AF.","claim_ids":["c1"],"hash":"996feafed9d5d49b3b00d641338f868493499e0214cb6f3b04636e3556467fa5"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28072796/","title":"Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis","quote":"The overall incidence of spontaneous resorption after LDH was 66.66% (95% CI 51% - 69%).","claim_ids":["c2"],"hash":"f0070309778a1f84e012891f03a0069fabfcfe2b95a3cd2440289bf81da7f6f8"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9396855/","title":"Characteristics and mechanisms of resorption in lumbar disc herniation","quote":"Macrophage infiltration and activation are critical steps in the process of reabsorption.","claim_ids":["c2"],"hash":"e60309eee0580676d90682f5c59f3fca8fd6b09f3e5d91b1dd27e24ae82f6c39"},{"id":"s4","type":"pubmed","url":"https://academic.oup.com/aje/article/179/8/929/108237","title":"Obesity as a Risk Factor for Sciatica: A Meta-Analysis","quote":"Both overweight (OR = 1.23) and obesity (OR = 1.40) were associated with lumbar radicular pain.","claim_ids":["c3"],"hash":"6ff65ee95ba89c5f9df8cb26b8086878a2e5ed0b0e5d762e09ede5e47477c674"},{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4751407/","title":"Disc in Flames: Roles of TNF-alpha and IL-1beta in Intervertebral Disc Degeneration","quote":"Inflammatory processes, exacerbated by cytokines TNF-alpha and IL-1beta are believed to be key mediators of disc degeneration and low back pain.","claim_ids":["c4"],"hash":"3685068619d028e38ffd474648ca22019c8872975512a4f69b2a3affd8d020e3"},{"id":"s6","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10313064/","title":"Mesenchymal stem cells can improve discogenic pain in patients with IVD degeneration: a meta-analysis","quote":"MSCs injection therapy may be effective in relieving discogenic low back pain and improving Oswestry Disability Index significantly","claim_ids":["c5"],"hash":"488449714a3913850bf6311ee0a9fd0546d567d6ed792416bd5f788a74ed20c6"},{"id":"s7","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/38908392/","title":"WalkBack: individualised progressive walking to prevent low back pain recurrence — randomised trial, 701 adults (Lancet 2024, PMID 38908392)","quote":"The intervention was effective in preventing an episode of activity-limiting low back pain (hazard ratio 0.72 [95% CI 0.60-0.85], p=0.0002). The median days to a recurrence was 208 days (95% CI 149-295) in the intervention group and 112 days (89-140) in the control group.","claim_ids":[],"hash":"08269f07512db558032dfccd9e5a6c91ea288b26ae01f7a37db4fe633e811a8c"},{"id":"s8","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/42243749/","title":"Causal links between multi-domain risk factors and disc degeneration: meta-analysis of 20 Mendelian randomization studies (BMC Musculoskelet Disord 2026, PMID 42243749)","quote":"Key lifestyle and metabolic risk factors were time watching TV (OR = 1.78, 1.52-2.08), smoking initiation (OR = 1.22, 1.12-1.33), greater height (OR = 1.14, 1.09-1.20), larger waist circumference (OR = 1.26, 1.04-1.53), body mass index (OR = 1.26, 1.14-1.38), triglycerides (OR = 1.08, 1.03-1.13), and Type 2 diabetes (OR = 1.05, 1.03-1.07).","claim_ids":[],"hash":"9437bcf26f9ff34c88f8d1d6c578130d1e226927869b213cf3d18d0325be8b74"},{"id":"s9","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/42542926/","title":"BPC-157, TB-500 and the two together on rat Achilles healing — 32 rats, 8 per arm (Jt Dis Relat Surg 2026, PMID 42542926)","quote":"Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone. ... The absence of additive effects with combination therapy may reflect convergence on shared downstream pathways; however, this hypothesis requires further experimental confirmation.","claim_ids":[],"hash":"6b1a89f7b5e94a6f2b9477c1f0dd192831e94e0797dda38d96ac6bda305a62be"},{"id":"s10","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/34580864/","title":"Exercise therapy for chronic low back pain (Cochrane 2021, 249 trials, PMID 34580864)","quote":"Exercise treatment ... is probably more effective than no treatment, usual care or placebo for pain and functional limitations in adults with chronic low back pain.","claim_ids":[],"hash":"89f2fa7996eff0960d5d17dcd58de7065eb5b62a18a74e9c49fa86c5a9db5d5e"},{"id":"s11","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/32272032/","title":"Weight-loss interventions for pain and disability in musculoskeletal disorders — 22 trials, 3,602 participants (JOSPT 2020, PMID 32272032)","quote":"For knee OA, there was low- to moderate-credibility evidence that weight-loss interventions were not more effective than exercise only for pain intensity and disability (4 trials, n = 673; SMD, -0.13; 95% CI: -0.40, 0.14).","claim_ids":[],"hash":"94e4998af6444260e0b7e02292c16b19b92d64f68f45bae8094f26fe353250fb"},{"id":"s12","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/37436929/","title":"15 g/day collagen peptides plus 15 weeks of resistance training, 39 men — tendon outcomes (Med Sci Sports Exerc 2023, PMID 37436929)","quote":"No between-group differences were detected for any of the tendinous tissue adaptations to RT (ANOVA group-time, 0.365 <= P <= 0.877).","claim_ids":[],"hash":"093a531144225f3431cf1aef1e33b64530810d78d446db3cbd8fdc3a8594506a"},{"id":"s13","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/39477425/","title":"Vitamin D supplementation for chronic low back pain — 10 randomised trials (In Vivo 2024, PMID 39477425)","quote":"The results indicated that vitamin D supplementation did not significantly reduce pain scores compared to control groups (SMD: -0.130, 95%CI=-0.260 to 0.000; I2=0%), regardless of participants' baseline vitamin D levels.","claim_ids":[],"hash":"19146135d9fe02b98e3c457eb02bf387803c61eae3b2faad9ecbf9a0456ee531"},{"id":"s14","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/23780532/","title":"Vertebral body fractures after lumbar epidural steroid injections — 3,000 injected vs 3,000 propensity-matched controls (JBJS Am 2013, PMID 23780532)","quote":"Each successive injection increased the risk of fracture by a factor of 1.21 (95% confidence interval, 1.08 to 1.30).","claim_ids":[],"hash":"2a29a3b8a9a1d5a0927843317ab01ed5bbbf1357aa376c9ab5c8c768b7e04d01"},{"id":"s15","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/41021423/","title":"Partial-night sleep restriction and pain sensitivity — 39 healthy volunteers, crossover (Scand J Pain 2025, PMID 41021423)","quote":"Experimental partial-night sleep restriction increases pain sensitivity, but does not alter inflammatory plasma biomarkers.","claim_ids":[],"hash":"2148c19b2e277e2733b3a107677dfe8734fa7afd4a13d9558037e133ee2b7639"},{"id":"s16","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/28475703/","title":"Cibinetide (ARA-290) phase 2b in sarcoidosis-associated small nerve fibre loss — 64 people, 28 days (IOVS 2017, PMID 28475703)","quote":"The placebo-corrected mean change from baseline CNFA at day 28 was 109 (95% CI, -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively.","claim_ids":[],"hash":"101a955fc55ee997e0bfc89c8555fdbfad407d00df136fa9592d54cc7033d123"},{"id":"s17","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/16568393/","title":"Rat discs after 8 weeks of smoke exposure and after stopping (J Orthop Sci 2006, PMID 16568393)","quote":"After cessation, progression of degeneration ceased ... However, there were no changes in annulus fibrosus misalignment. Interleukin-1beta levels also remained significantly elevated after 8 weeks of cessation.","claim_ids":[],"hash":"7041f62426aa6034aef29ea9728fa8141443c581f45dbbc28b4fac4c9bf6c693"},{"id":"s18","type":"source","url":"https://clinicaltrials.gov/study/NCT07035093","title":"NCT07035093 — retatrutide in people with obesity or overweight and chronic low back pain, phase 3, 586 participants (Eli Lilly)","quote":"Primary outcomes: Change from Baseline in Pain Intensity Per Numeric Rating Scale; Percent Change from Baseline in Body Weight. Baseline, up to 72 weeks. Status: active, not recruiting. Start 2025-05-29. Estimated primary completion 2027-09.","claim_ids":[],"hash":"dc70f6bda99fd41c176f50207ee31f57de7cc44662be45c22ad0ff33beb097b5"},{"id":"s19","type":"source","url":"https://clinicaltrials.gov/study/NCT07437547","title":"NCT07437547 — BPC-157 for acute hamstring muscle strain, phase 2, 120 participants (Hudson Biotech)","quote":"Primary outcomes: Time to return to unrestricted sport participation (days), 8 weeks; Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), blinded central radiology review. Status: recruiting. Actual start 2026-02-02. Estimated primary completion 2027-02-14.","claim_ids":[],"hash":"ccfe6e249395fdfc7ad3d3fd5259e06d3b709ba3bb3d2b8d19355ef7b5f92764"},{"id":"s20","type":"source","url":"https://clinicaltrials.gov/study/NCT07487363","title":"NCT07487363 — a record that declares itself a fictional example, written in the style of a TB-500 (thymosin beta-4 17-23 fragment) study of cardiovascular biomarkers in stable atherosclerotic disease, phase 1/2, 80 participants (Hudson Biotech)","quote":"Primary outcomes: incidence of treatment-emergent adverse events, 12 weeks; incidence of serious adverse events, 28 days. Status: recruiting. Actual start 2026-02-05. Estimated primary completion 2027-02-14.","claim_ids":[],"hash":"632d5a5aebb71cc2cf574c6a8dcb6874288e31202326c85b457b4106f7243db9"},{"id":"s21","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/32297973/","title":"Anti-inflammatory drugs for acute low back pain — 32 trials, 5,356 participants (Cochrane 2020, PMID 32297973)","quote":"NSAIDs reduced pain ... mean difference -7.29, 95% CI -10.98 to -3.61 on a 0 to 100 scale ... the magnitude of these effects is small and probably not clinically relevant.","claim_ids":[],"hash":"ba6674b477c4c388fec19431863962054e3a26ff0ab7854862f57a402b6a1da8"},{"id":"s22","type":"source","url":"https://x.com/thebillyboone/status/2082100039707427193","title":"Herniated L4-L5, three weeks on BPC-157 with TB-500, back on the court (anecdotal, X, 2026-07-28)","quote":"Herniated L4-L5 disc 3 weeks ago hopped on the Wolverine stack (BPC-157/TB-500) This is today Took me 2 months to get back on the court last time","claim_ids":[],"hash":"8ed824c44d895705f84ec6f670f09cf53ea4cc2eb469f093e8ac54ba311083f8"},{"id":"s23","type":"source","url":"https://x.com/jasonsvoboda/status/2081426443024961838","title":"Severe L4/L5/S1 herniation and a degeneration diagnosis, pain-free within a month on the pair (anecdotal, X, 2026-07-26)","quote":"BPC-157 / TB-500 Blew up my back in 2017. L4/L5/S1 severe disc herniation. Doc diagnosed me with degenerative disc disease... Found the Wolverine stack and within a month I was pain free.","claim_ids":[],"hash":"d2f43df5247d8a5c48caa98e41f531e62622f65b8c4fb3b211bb2a507e22896f"},{"id":"s24","type":"source","url":"https://x.com/cryptorayray89/status/2081141222719045707","title":"ARA-290 plus BPC-157 plus TB-500 for one month after back surgery, sciatica reported 95% gone (anecdotal, X, 2026-07-25)","quote":"I've been taking Ara290 and BPC 157 and Tb500 (Wolverine Stack) for 1 month so far and my sciatica is 95% gone. I've had major back surgery and have never had relief as well as I do now.","claim_ids":[],"hash":"94ac3d5c98a45496ea87924444871e0d9c378e94cb09235016afeceda0a2c41c"},{"id":"s25","type":"source","url":"https://x.com/KateinMB/status/2080854619593363787","title":"Lower spine degeneration, reported pain-free on BPC-157 with TB-500, still dosing (anecdotal, X, 2026-07-25)","quote":"I have disc degeneration in lower spine. Could barely get upright. BPC157 and TB500 made me pain free. (On maint/dose)","claim_ids":[],"hash":"00f7b40cdc3b4b57d79dc91b9ebc234d16bd0defbcd0525f777f3553f1db0750"},{"id":"s26","type":"source","url":"https://x.com/BrandBarons/status/2080279766796562881","title":"One month of the pair for lifelong back pain — recovery faster, pain still present (anecdotal, X, 2026-07-23)","quote":"One month into the Wolverine stack (BPC-157 + TB-500). Lifelong chronic back pain. Lift 3x a week. Tweaked it yesterday... woke up this morning and it already felt better. Pain still there, but the recovery is noticeable.","claim_ids":[],"hash":"972068d12d518e9cd2fd88b60132bb8ae07a462a55adf6173575980cd5ac1afb"},{"id":"s27","type":"source","url":"https://x.com/yakyusenshu23/status/2074846700674674986","title":"Retatrutide alongside a BPC-157/TB-500 blend, low back reported improved (anecdotal, X, 2026-07-08)","quote":"Reta has basically taken alcohol out of my life by 90%+... I do feel like bpc-157/tb500 blend has improved my joint and low back health immensely","claim_ids":[],"hash":"9c81149649a52e80b1af1d626e2898757af4e9b5c0d3df583a8fe95ec4a49a87"},{"id":"s28","type":"source","url":"https://x.com/mannyjplays/status/2062148959976526143","title":"Three compounds at once for back pain, cleared in three to four weeks (anecdotal, X, 2026-06-03)","quote":"I took BPC157, TB500 and ghk-cu for some pretty gnarly back pain and it cleared it within a 3-4 weeks... Ara 290 is specifically for nerve regeneration.","claim_ids":[],"hash":"b42b37ab6c9d9898a25a41d307ee7be3b67041f5a4cb5934358d6e0a441f4d01"},{"id":"s29","type":"source","url":"https://x.com/MuroCrypto/status/2083184469956059529","title":"Six weeks of the pair — shoulder and biceps resolved, the disc only partly (anecdotal, X, 2026-07-31)","quote":"My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc... In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better.","claim_ids":[],"hash":"a7921e41b9e6967b8bef4fb6a69504f324df60aa3ae8290e55411634bfe6dfce"},{"id":"s30","type":"source","url":"https://x.com/L0V3lsKeY/status/2083868515438666186","title":"Severe leg pain, reported gone over three days on BPC-157 with TB-500 (anecdotal, X, 2026-08-02)","quote":"Testimony regarding BPC-157/TB500 Peptides. Wednesday I woke up in severe pain in my L Leg... Peptides started in the afternoon. Leg 75% better in the evening... Friday: Woke up 90% better... Saturday: Woke up 100% better.","claim_ids":[],"hash":"c243e7ada8a847e8e4e7176c7e212ec2189dc366a706ad86bbd492e5ec220d5c"},{"id":"s31","type":"source","url":"https://x.com/jakew/status/2057454035855094005","title":"The pair called a waste of money for joint damage (anecdotal, X, 2026-05-21)","quote":"My experience with BPC-157 and what I've observed in others is that Wolverine and GLOW are a waste of money if you're dealing with damage to a joint.","claim_ids":[],"hash":"50b34edf3842fc49a17b8a214cbbd06ac69459bf988897e299c55470de4984c0"},{"id":"s32","type":"source","url":"https://x.com/franchupardo/status/2082241971582579132","title":"Two months of the pair for knees — slight improvement, sleep and heart-rate variability disrupted until stopping (anecdotal, X, 2026-07-28)","quote":"I used BPC-157 and TB-500 for my knees for two months. I noticed a slight improvement, but it really messed with my sleep... once I stopped taking them, my sleep and HRV went back to normal.","claim_ids":[],"hash":"790fb70c4c1740612a6005067a6594bbbd4aa26b16d609c46e10cfd33298550a"},{"id":"s33","type":"source","url":"https://x.com/NewsAsset/status/2080378902984458706","title":"L5/S1 herniation, BPC-157 alone and deliberately unpaired, 90% pain reduction in two weeks (anecdotal, X, 2026-07-23)","quote":"I took it for my L5/S1 herniated disc and it didn't take months to get better like before. It took 2 weeks to reduce the pain by 90%. Just BPC-157. I didn't pair it with TB500","claim_ids":[],"hash":"95718866443645f67b95cbd4c7bc4a87b133bd1220560099a0e81cd819a153f0"},{"id":"s34","type":"source","url":"https://x.com/derek_j_scv/status/2056494210963107983","title":"BPC-157 worked on a wrist and did nothing for the same person's herniated disc (anecdotal, X, 2026-05-18)","quote":"I have a herniated disc. BPC157 healed the ligaments and tendon damage in my wrist. Did nothing for my disc. It only works on skeletal muscle, ligaments and tendons.","claim_ids":[],"hash":"613e441f3e31362d7cdd42c698f618ae45d28f001a0883d8556f23b294bf8476"},{"id":"s35","type":"source","url":"https://x.com/NICKELL11b/status/2049997364883030236","title":"A week of BPC-157 to avoid neck surgery, surgery happened anyway (anecdotal, X, 2026-04-30)","quote":"I've never used any of these other than BPC 157 for a week straight.. I was trying to avoid having neck surgery, but it didn't work out that way.","claim_ids":[],"hash":"760f158904914ad813fcecf5e0fc0a04bed98ad3b3dea062863a586e09b42905"},{"id":"s36","type":"source","url":"https://x.com/PeptideRookie/status/2043371104731910313","title":"One of the two did nothing for a back injury, the other cleared it in five days (anecdotal, X, 2026-04-12)","quote":"You might need TB500. I used one for a back injury and it did nothing, switched to the other and it was gone within 5 days.","claim_ids":[],"hash":"bdd74bb90baa851b3e5a666ac4572c385d52951bf1e2f6bc9095b177db28f828"},{"id":"s37","type":"source","url":"https://x.com/AhaSahhDude/status/2027919309620609260","title":"Oral BPC-157 capsules did not help a back problem (anecdotal, X, 2026-03-01)","quote":"Can you give me more details about the BPC-157? I've only taken it over capsule the injections weren't available then. Didn't help my back but I'd be curious if the injections would now.","claim_ids":[],"hash":"30bf3ac176b4777af21c7026e37c75a0302c116621d93d544080a431ba592175"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9820240/","title":"Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration","quote":"The IVD is one of the avascular tissues which only received small arteries supplying the outermost peripheral fibers of the AF.","claim_ids":["c1"],"hash":"996feafed9d5d49b3b00d641338f868493499e0214cb6f3b04636e3556467fa5"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28072796/","title":"Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis","quote":"The overall incidence of spontaneous resorption after LDH was 66.66% (95% CI 51% - 69%).","claim_ids":["c2"],"hash":"f0070309778a1f84e012891f03a0069fabfcfe2b95a3cd2440289bf81da7f6f8"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9396855/","title":"Characteristics and mechanisms of resorption in lumbar disc herniation","quote":"Macrophage infiltration and activation are critical steps in the process of reabsorption.","claim_ids":["c2"],"hash":"e60309eee0580676d90682f5c59f3fca8fd6b09f3e5d91b1dd27e24ae82f6c39"},{"id":"s4","type":"pubmed","url":"https://academic.oup.com/aje/article/179/8/929/108237","title":"Obesity as a Risk Factor for Sciatica: A Meta-Analysis","quote":"Both overweight (OR = 1.23) and obesity (OR = 1.40) were associated with lumbar radicular pain.","claim_ids":["c3"],"hash":"6ff65ee95ba89c5f9df8cb26b8086878a2e5ed0b0e5d762e09ede5e47477c674"},{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4751407/","title":"Disc in Flames: Roles of TNF-alpha and IL-1beta in Intervertebral Disc Degeneration","quote":"Inflammatory processes, exacerbated by cytokines TNF-alpha and IL-1beta are believed to be key mediators of disc degeneration and low back pain.","claim_ids":["c4"],"hash":"3685068619d028e38ffd474648ca22019c8872975512a4f69b2a3affd8d020e3"},{"id":"s6","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10313064/","title":"Mesenchymal stem cells can improve discogenic pain in patients with IVD degeneration: a meta-analysis","quote":"MSCs injection therapy may be effective in relieving discogenic low back pain and improving Oswestry Disability Index significantly","claim_ids":["c5"],"hash":"488449714a3913850bf6311ee0a9fd0546d567d6ed792416bd5f788a74ed20c6"}],"user_reports":[],"related_articles":[{"slug":"bpc-157","title":"BPC-157: Body Protection Compound","claims":[{"id":"c1","text":"BPC-157 is a made-in-a-lab chain of 15 amino acids, copied from a stretch of a protein found in stomach juice.","tier":"human"},{"id":"c2","text":"More than 100 studies in animals and in cells report faster healing — better-organised collagen, and blood vessels growing into the wound — across tendon, gut, muscle, bone and nerve.","tier":"preclinical"},{"id":"c3","text":"A 2025 pilot study dripped up to 20 mg of BPC-157 into the veins of two healthy adults. Nothing went wrong with their vital signs, their blood tests, or how they said they felt.","tier":"human"},{"id":"c4","text":"The proposed explanation is that BPC-157 encourages new blood vessel growth at the injury and works on the body’s nitric oxide system. That is a proposal drawn from animal work, not something measured in a person.","tier":"mechanistic"},{"id":"c6","text":"One person reported feeling sick within two weeks of starting BPC-157 and stopped taking it. That is one person. The same account was then ingested 25 more times from other copies of the same thread, and each copy is listed below so the count is visible rather than hidden.","tier":"anecdotal"},{"id":"c8","text":"The second copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 2 people.","tier":"anecdotal"},{"id":"c10","text":"The third copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 3 people.","tier":"anecdotal"},{"id":"c11","text":"Ten of the sources catalogued on this page are vendors and clinics selling BPC-157. That is marketing material, and it is listed here as marketing material rather than as evidence.","tier":"human"}]},{"slug":"tb-500","title":"TB-500: a seven-amino-acid fragment sold under the name of the protein thymosin beta-4","claims":[{"id":"c1","text":"TB-500 is sold as a made-in-a-lab version of thymosin beta-4, a small protein your own cells already make.","tier":"mechanistic"},{"id":"c300","text":"Thymosin beta-4 is the body's main handler of loose actin, the building material a cell uses to change shape and crawl.","tier":"mechanistic"},{"id":"c301","text":"Holding that building material is how thymosin beta-4 sets the pace at which cells move into an injury, and cells moving into an injury is what repair is.","tier":"mechanistic"},{"id":"c2","text":"The same seven amino acids that let thymosin beta-4 grip actin also make new blood vessels grow.","tier":"mechanistic"},{"id":"c302","text":"Those seven amino acids also make the cells that line blood vessels crawl, so new blood vessel growth is not a side effect of the repair. It is part of it.","tier":"mechanistic"},{"id":"c3","text":"In controlled animal wound experiments, thymosin beta-4 made skin grow back across the wound 42 to 61% faster than in untreated animals.","tier":"preclinical"},{"id":"c303","text":"Those same animal wounds laid down more collagen and grew more new blood vessels.","tier":"preclinical"},{"id":"c4","text":"Thymosin beta-4, the full protein rather than the fragment in the vial, was tested in people with pressure sores and long-standing leg ulcers in proper randomised, double-blind, placebo-controlled trials.","tier":"human"}]},{"slug":"ara-290","title":"ARA-290 (cibinetide): a fragment of erythropoietin that acts on nerves, not on blood","claims":[{"id":"c1","text":"ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.","tier":"mechanistic"},{"id":"c2","text":"Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding EPO's thrombotic risk.","tier":"mechanistic"},{"id":"c3","text":"The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.","tier":"mechanistic"},{"id":"c4","text":"In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom scores versus placebo.","tier":"human"},{"id":"c5","text":"In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an objective structural sign of nerve regeneration.","tier":"human"},{"id":"c6","text":"In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.","tier":"human"},{"id":"c7","text":"In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory response.","tier":"preclinical"},{"id":"c8","text":"ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.","tier":"preclinical"}]},{"slug":"retatrutide","title":"Retatrutide: the third receptor, and what the evidence now establishes","claims":[{"id":"rc-mech","text":"Retatrutide is a single synthetic peptide that agonizes three receptors at once — GLP-1, GIP, and glucagon (GCGR).","tier":"mechanistic"},{"id":"rc-mech2","text":"Glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation, adding an energy-output arm on top of the appetite-suppressing GLP-1/GIP arms.","tier":"mechanistic"},{"id":"rc-obesity","text":"In adults with obesity, meta-analysis finds retatrutide produces large, dose-dependent body-weight reductions, statistically and clinically superior to placebo, with the highest doses approaching ~24% at ~48 weeks.","tier":"human"},{"id":"rc-t2d","text":"In type 2 diabetes, a Phase 2 substudy found retatrutide significantly improved total body-fat-mass reduction versus both placebo and dulaglutide.","tier":"human"},{"id":"rc-safety","text":"Adverse events are the dose-dependent incretin profile — nausea, diarrhea, vomiting; a safety review found the profile acceptable but did not establish long-term safety.","tier":"human"},{"id":"rc-phase3","text":"The Phase 3 TRIUMPH program is ongoing and retatrutide is not approved by any regulator as of writing; everything here is investigational trial data.","tier":"runtime"},{"id":"rc-ruo","text":"This is a research-use-only compound. The article reports trial data; it is not medical advice and does not establish a treatment for any person.","tier":"runtime"}]},{"slug":"degenerative-disc-disease","title":"Degenerative Disc Disease","claims":[{"id":"c1","text":"Degeneration starts as a failure to hold water. The soft centre of the disc loses aggrecan, the molecule that pins water in place, and the water leaves with it.","tier":"mechanistic"},{"id":"c320","text":"A disc is roughly 90% water at birth and around 70% by age 60. Once it is that dry it can no longer hold pressure and share the load the way it is supposed to.","tier":"mechanistic"},{"id":"c2","text":"The disc heals badly because it is the largest structure in the body with no blood supply of its own. Everything it needs seeps slowly in through the bony plates above and below it.","tier":"mechanistic"},{"id":"c3","text":"Once the centre has dried out, the load shifts onto the tough outer ring, which starts to crack and tear. The disc does try to repair itself, but the breaking down keeps running ahead of the repair.","tier":"mechanistic"},{"id":"c4","text":"Two inflammatory signals, TNF-alpha and IL-1beta, do most of the driving in disc degeneration and in pain that comes from the disc itself. The disc's own cells are what make them.","tier":"mechanistic"},{"id":"c321","text":"Those same two signals coax nerve fibres to grow into a disc that in health has no nerves inside it at all.","tier":"mechanistic"},{"id":"c5","text":"In a controlled rat study, injecting TNF-alpha produced both pain and degeneration, and blocking it at the moment of injury stopped both from appearing. That makes TNF-alpha a cause and not just a marker.","tier":"preclinical"},{"id":"c6","text":"TNF-alpha tips the disc's building-and-breaking balance towards breaking. It raises the enzymes that chew up the disc's scaffolding, called MMPs, faster than it raises the TIMPs that hold those enzymes back.","tier":"mechanistic"}]}],"question_graph":{"slug":"the-disc-stack","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":37,"anecdotal":0,"scientific":6,"user_reports":0,"questions":0,"evidence_ingests":0}}